Kidney International Reports最新文献

{"title":"WCN26-5099 EFFICACY AND SAFETY OF A TARGETED-RELEASE FORMULATION OF BUDESONIDE (HR19042 CAPSULES) IN PATIENTS WITH PRIMARY IgA NEPHROPATHY: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 2/3 TRIAL","authors":"Xiaobing Yang ∗ , Wei Chen , Lihua Wang , Jun Xue , Leyi Gu , Wenxiu Chang , Gang Xu , Bicheng Liu , Liang Wang , Ping Luo , Rong Wang , Su Zhang , Rong Huang , Fanfan Hou","doi":"10.1016/j.ekir.2026.106506","DOIUrl":"10.1016/j.ekir.2026.106506","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106506"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multicenter Randomized Clinical Trial of Dapagliflozin in Patients Receiving Chronic Dialysis (The DARE-ESKD-2 Trial)","authors":"Joaquim Barreto ,&nbsp;Marilia Paiva Martins ,&nbsp;Cleide Aparecida Moreira Silva ,&nbsp;Daniel Campos Jesus ,&nbsp;Mariana Baldini ,&nbsp;Ana Luisa Oliveira ,&nbsp;Kelcia Rosana da Silva Quadros ,&nbsp;Cinthia Esbrile Moraes Carbonara ,&nbsp;Gustavo L.R. Silva ,&nbsp;Alessandra M. Campos-Staffico ,&nbsp;André Zimerman ,&nbsp;Filipe Moura ,&nbsp;Otavio R. Coelho-Filho ,&nbsp;Jose Roberto Matos-Souza ,&nbsp;Barbara Assato ,&nbsp;Isabela Bonilha ,&nbsp;Erica Gomes ,&nbsp;Sheila T. Kimura-Medorima ,&nbsp;Wilson Nadruz ,&nbsp;Rodrigo Bueno Oliveira ,&nbsp;Andrei C. Sposito","doi":"10.1016/j.ekir.2026.106355","DOIUrl":"10.1016/j.ekir.2026.106355","url":null,"abstract":"<div><h3>Introduction</h3><div>Dapagliflozin reduces heart failure (HF) incidence and hospitalizations in chronic kidney disease (CKD), but its efficacy and safety in patients on maintenance dialysis remain uncertain.</div></div><div><h3>Methods</h3><div>In this prospective, randomized, open-label, blinded end point trial performed at 3 dialysis clinics between January 2023 and September 2024, adults on chronic dialysis were randomized to once daily dapagliflozin 10 mg or standard care for 24 weeks. The primary end point was change in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. Secondary end points included changes in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores and 6-minute walk test distance (6MWTD). Exploratory analysis examined intergroup differences in echocardiographic measurements and laboratory tests. Safety analysis comprised adverse event rates.</div></div><div><h3>Results</h3><div>Of 110 screened individuals, 80 were consecutively assigned (mean age: 56 years; 54% male). The median (95% confidence interval [CI]) adjusted change in NT-proBNP was 13 (−64 to 281) pg/ml in the control group and −109 (−356 to 55) pg/ml in the dapagliflozin group. The intergroup difference in NT-proBNP change was not statistically significant after adjustment by baseline values (median [95% CI] difference: −155 [−327 to −33] pg/ml; <em>P</em> = 0.065). No difference was found between study arms regarding the least mean (95% CI) square difference (LSD) in KCCQ clinical summary score (7 points; <em>P</em> = 0.073), total summary score (7 points; <em>P</em> = 0.094), or 6MWTD (−0.9 m; <em>P</em> = 0.956). Dapagliflozin did not increase the proportion of patients with improvement in 6MWTD (34.5% vs. 40.0%; odds ratio [OR]: 1.27 [95% CI: 0.44–3.74]; <em>P</em> = 0.657) or KCCQ clinical summary score (18.8% vs. 22.9%; OR: 1.63 [95% CI: 0.33–9.12]; <em>P</em> = 0.548). No difference was found between study arms regarding echocardiographic measurements or safety end points.</div></div><div><h3>Conclusion</h3><div>Dapagliflozin was safe but did not affect surrogate markers of HF compared with standard care in patients receiving maintenance dialysis, suggesting no demonstrable cardiovascular benefit over 24 weeks in this population.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 4","pages":"Article 106355"},"PeriodicalIF":5.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147612630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding Kidney Care: How Nonphysician Health Workers Can Address the Global CKD Crisis","authors":"C. Elena Cervantes ,&nbsp;Daniel V. O’Hara ,&nbsp;Ana Catalina Alvarez-Elias ,&nbsp;Yogeshni Chandra ,&nbsp;Marek Kollar ,&nbsp;Tae Won Yi ,&nbsp;Rasha Hussein ,&nbsp;Mythri Shankar ,&nbsp;Priti Meena ,&nbsp;Becky Mingyao Ma ,&nbsp;Chimezie Godswill Okwuonu ,&nbsp;Vivekanand Jha","doi":"10.1016/j.ekir.2025.09.037","DOIUrl":"10.1016/j.ekir.2025.09.037","url":null,"abstract":"<div><div>The current global nephrology workforce is insufficient to meet the increasing burden of chronic kidney disease (CKD) and kidney failure. Nonphysician health workers (NPHWs) may be well-placed to fill the gap and deliver guideline-aligned care. We review the range of NPHW categories and care models that could be enlisted in different health care settings; the range of contributions that could be made for CKD prevention, education, screening, management, and monitoring; the existing and required resources to support NPHWs; and technological advancements that can help alleviate the workload. Through analysis of collaborative approaches and existing alternative care delivery models, we aimed to provide insights into how such programs can be successfully implemented to augment the existing health workforce to deliver effective care and improve outcomes of people with and at risk of developing kidney disease worldwide.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103625"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145929212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting Vincristine for FSGS: Proof-of-Mechanism Arrives, but Whom Should We Treat?","authors":"Wenjie Guo ,&nbsp;Jie Luo ,&nbsp;Zhixiao Li ,&nbsp;Xue Li ,&nbsp;Yingying Zhang ,&nbsp;Jingyi Yang","doi":"10.1016/j.ekir.2025.103749","DOIUrl":"10.1016/j.ekir.2025.103749","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103749"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146035549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Randomized Controlled Trial on the Efficacy of Reduced-Dose Cyclical Corticosteroids and Cyclophosphamide in Primary Membranous Nephropathy” [Kidney International Reports Volume 10, Issue 11, November 2025, Pages 3785-3795]","authors":"Raja Ramachandran ,&nbsp;Prabhat Chauhan ,&nbsp;Joyita Bharati ,&nbsp;Manisha Sahay ,&nbsp;Indranil Ghosh ,&nbsp;Vivek Sood ,&nbsp;Thakur Sain ,&nbsp;Prabhjot Kaur ,&nbsp;Vinod Kumar ,&nbsp;Arun Prabhahar ,&nbsp;Ritambhra Nada ,&nbsp;Jasmine Sethi ,&nbsp;Smita Divyaveer ,&nbsp;Manish Rathi ,&nbsp;Harbir Kohli ,&nbsp;Vivekanand Jha","doi":"10.1016/j.ekir.2025.103768","DOIUrl":"10.1016/j.ekir.2025.103768","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103768"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146035551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rescue Therapy With Pegcetacoplan in a Patient With Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits","authors":"Hormaz Dastoor ,&nbsp;Emad Khater ,&nbsp;Suhail Al Salam ,&nbsp;Stephen G. Holt","doi":"10.1016/j.ekir.2026.103770","DOIUrl":"10.1016/j.ekir.2026.103770","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103770"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146078957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes of IgM-Positive Plasma Cell Tubulointerstitial Nephritis","authors":"Naoki Takahashi ,&nbsp;Haruyoshi Yoshida ,&nbsp;Hideki Kimura ,&nbsp;Chie Yamamoto ,&nbsp;Makoto Yamamoto ,&nbsp;Nanami Iwamura ,&nbsp;Kohei Matsuta ,&nbsp;Sho Nishikawa ,&nbsp;Kazuhisa Nishimori ,&nbsp;Sachiko Fukushima ,&nbsp;Yudai Nishikawa ,&nbsp;Mamiko Kobayashi ,&nbsp;Kenji Kasuno ,&nbsp;Hironobu Naiki ,&nbsp;Masayuki Iwano ,&nbsp;Tadashi Toyama","doi":"10.1016/j.ekir.2025.103764","DOIUrl":"10.1016/j.ekir.2025.103764","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103764"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 Inhibitors and Long-Term Outcomes After AKI","authors":"Anyarin Wannakittirat ,&nbsp;Veerapatr Nimkietkajorn ,&nbsp;Peerapat Thanapongsathorn ,&nbsp;Weerachai Chaijamorn ,&nbsp;Nattira Sorose ,&nbsp;Akarathep Leewongworasingh ,&nbsp;Khanitha Yimsangyad ,&nbsp;Nuttha Lumlertgul ,&nbsp;Sadudee Peerapornratana ,&nbsp;Nattachai Srisawat","doi":"10.1016/j.ekir.2025.103752","DOIUrl":"10.1016/j.ekir.2025.103752","url":null,"abstract":"<div><h3>Introduction</h3><div>Currently, there is no specific treatment for post–acute kidney injury (AKI) survivors, one of the highest risk groups of the renal and nonrenal adverse long-term outcomes. This study aimed to determine whether the sodium-glucose cotransporter-2 inhibitor (SGLT2i) can decrease 1-year major adverse kidney events (MAKE365) in post-AKI setting.</div></div><div><h3>Methods</h3><div>Multicenter randomized controlled trial, involving severe AKI survivors from 3 tertiary care hospitals, who were dialysis independent, and had an estimated glomerular filtration rate (eGFR) ≥ 20 ml/min per 1.73 m². The participants were randomized to receive empagliflozin 10 mg/d or matching placebo for 1 year after the incident AKI. The primary outcome was MAKE365, defined as a composite of persistent kidney dysfunction (a sustained decrease in eGFR ≥ 25% or increase in serum creatinine ≥ 200% of baseline), the need for long-term dialysis, or death at 1 year after the incident of AKI.</div></div><div><h3>Results</h3><div>A total of 200 participants were included in this study, 98 patients in empagliflozin group and 102 patients in placebo group; AKI stage 3 was predominant, with renal replacement therapy required for 30% and 23% of patients in each group, respectively. On modified intention-to-treat analysis, MAKE365 occurred in 35% in the empagliflozin group and 36% in the placebo group (<em>P</em> = 0.82). The incident rate ratio indicated a significant reduction in recurrent AKI in the empagliflozin group (34 vs. 66 per 100 person-years, respectively; incident rate ratio: 0.51, 95% confidence interval [CI]: 0.31–0.84; <em>P</em> = 0.008).</div></div><div><h3>Conclusion</h3><div>Empagliflozin could not show reduction in MAKE365 but showed potential benefits in reducing recurrent AKI.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103752"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146180902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD","authors":"Ajay K. Singh ,&nbsp;Stefan D. Anker ,&nbsp;Bertram Pitt ,&nbsp;Peter Rossing ,&nbsp;Luis M. Ruilope ,&nbsp;Christiane Ahlers ,&nbsp;Youssef M.K. Farag ,&nbsp;Marc Lambelet ,&nbsp;Meike D. Brinker ,&nbsp;Katja Rohwedder ,&nbsp;Gerasimos Filippatos ,&nbsp;FIDELIO-DKD and FIGARO-DKD Investigators","doi":"10.1016/j.ekir.2025.10.032","DOIUrl":"10.1016/j.ekir.2025.10.032","url":null,"abstract":"<div><h3>Introduction</h3><div>Finerenone demonstrated kidney and cardiovascular benefits in participants with chronic kidney disease (CKD) and type 2 diabetes (T2D) on optimized renin-angiotensin system (RAS) inhibition in FIDELITY, a pooled individual-level analysis of 2 clinical trials. Considering that treatment recommendations increasingly support combination therapies for CKD and T2D, this FIDELITY subanalysis assessed the efficacy and safety of finerenone versus placebo when taken with concomitant sodium-glucose cotransporter-2 inhibitor (SGLT-2i) and/or glucagon-like peptide-1 receptor agonist (GLP-1RA).</div></div><div><h3>Methods</h3><div>Change in urine albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR) and systolic blood pressure (SBP) over time, and treatment-emergent adverse events (TEAEs) were analyzed in subgroups by concomitant medication at baseline as follows: (i) combined SGLT-2i and GLP-1RA (<em>n</em> = 167), (ii) no SGLT-2i or GLP-1RA (<em>n</em> = 11,341), (iii) SGLT-2i only (<em>n</em> = 706), and (iv) GLP-1RA only (<em>n</em> = 776).</div></div><div><h3>Results</h3><div>Finerenone led to a greater reduction than with placebo in UACR and SBP from baseline to month 4 across all concomitant medication subgroups. At month 12, the greatest UACR reduction difference between the treatment arms was observed in the finerenone subgroup with combined SGLT-2i and GLP-1RA. Decline of eGFR from baseline was slower with finerenone than with placebo across all subgroups. The safety profile of finerenone was not modified by concomitant SGLT-2i and/or GLP-1RA use; hyperkalemia events leading to treatment discontinuation or hospitalization with finerenone were low.</div></div><div><h3>Conclusion</h3><div>The concomitant use of finerenone with SGLT-2i and/or GLP-1RA demonstrated potential synergistic effects on preserving kidney function and reducing blood pressure versus placebo in people with CKD and T2D.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103704"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146035485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy","authors":"Matias Trillini ,&nbsp;Valentina Portalupi ,&nbsp;Alessia Gennarini ,&nbsp;Livia Surdi ,&nbsp;Annachiara Currado ,&nbsp;Maddalena Marasà ,&nbsp;Manuel Alfredo Podestà ,&nbsp;Alessandro Villa ,&nbsp;Tobia Peracchi ,&nbsp;Diego Fidone ,&nbsp;Nadia Rubis ,&nbsp;Olimpia Diadei ,&nbsp;Chiara Guarinoni ,&nbsp;Federica Casiraghi ,&nbsp;Marta Todeschini ,&nbsp;Daniela Cugini ,&nbsp;Fabiola Carrara ,&nbsp;Davide Martinetti ,&nbsp;Paola Rizzo ,&nbsp;Giuseppe Remuzzi ,&nbsp;Piero Ruggenenti","doi":"10.1016/j.ekir.2025.103728","DOIUrl":"10.1016/j.ekir.2025.103728","url":null,"abstract":"<div><h3>Introduction</h3><div>Approximately 30% of patients with primary membranous nephropathy (MN) and persistent nephrotic syndrome (NS) fail rituximab therapy through mechanisms that could be overcome by obinutuzumab.</div></div><div><h3>Methods</h3><div>In this prospective, single-arm, single-center, open-label trial, 20 consenting adults with MN and rituximab-resistant NS received three 1000 mg obinutuzumab infusions at the Bergamo Nephrology Unit (Italy) between March 2022 and February 2024 and were monitored for ≤ 12 months. The primary outcome was a composite end point of normo-albuminemia and complete (proteinuria &lt; 0.3 g/d) or partial (proteinuria &lt; 3.5 g/d with ≥ 50% reduction from baseline) NS remission at 12-month follow-up. Twenty-four-hour proteinuria and glomerular filtration rate (GFR) were evaluated at baseline and at 3, 6, 9, 12, 18, and 24 months posttreatment.</div></div><div><h3>Results</h3><div>At 12 months, 16 patients met the combined end point, 4 with complete remission. No patient relapsed after remission. Median (interquartile range) 24-h proteinuria decreased from 5.7 (4.7–8.1) to 1.3 (0.5–2.7) g/24 h. Albumin and IgG fractional clearances also decreased, whereas serum albumin increased from 2.9 ± 0.6 g/dl to 3.9 ± 0.3 g/dl (<em>P</em> &lt; 0.0001 for all changes). Dyslipidemia, hypocalcemia, and hypo-gammaglobulinemia improved significantly and GFR stabilized. At 12 months, total B cells and circulating anti–phospholipase A₂ receptor (PLA₂R) antibodies were depleted. Similar findings were observed in the cohort of 10 patients who completed 24 months of follow-up. However, total B cells reemerged in the circulation without an increase in anti-PLA₂R antibodies and proteinuria, or relapses. Treatment was safe and well-tolerated.</div></div><div><h3>Conclusion</h3><div>Obinutuzumab treatment is extremely effective and safe in patients with MN and rituximab-resistant NS and can achieve persistent remission in this population.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103728"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146035555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}